Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with locally advanced BCC and metastatic BCC
Patients with adequate bone marrow, liver, and renal function
You may not be if
Patients who had had major surgery within 4 weeks of initiation of study medication
Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes.
Patients with concurrent medical conditions that may interfere or potentially affect the interpretation of the study.
Patients with neuromuscular disorders or are on concurrent treatment with drugs that may cause muscle damage.
Patients who were on concurrent therapy with other anti-neoplastic agents.
Patients who had taken part in an experimental drug within 4 weeks of initiation of study medication.
Pregnant or nursing (lactating) women
Women of child bearing potential unwilling to use 2 forms of highly effective contraception throughout the study and for 3 months after the last treatment
Fertile males not willing to use condoms throughout the study and for 3 months after the last treatment.
Patients who were unwilling or unable to comply with the protocol.
Clareo Health | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
